Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma

@article{Yang2011ParvovirusBI,
  title={Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma},
  author={S. Yang and Long-Wei Lin and Yu-Jen Fang and A. Cheng and S. Kuo},
  journal={Annals of Hematology},
  year={2011},
  volume={91},
  pages={291-294}
}
Dear Editor, Diffuse large B-cell lymphoma (DLBCL) of the gastrointestinal tract is the most common subtype of extranodal non-Hodgkin’s lymphoma [1]. Recent studies indicated that addition of rituximab to a chemotherapy regimen significantly improved the outcome of patients with DLBCL [2]. However, serious viral infections from hepatitis B virus (HBV), cytomegalovirus (CMV), varicella-zoster virus (VZV), or parvovirus B19 can occur in lymphoma patients treated with rituximab regimens [3… Expand
9 Citations
Parvovirus B 19 Associated Hepatitis
Parvovirus B19 Associated Hepatitis

References

SHOWING 1-10 OF 12 REFERENCES
Rituximab-related viral infections in lymphoma patients
Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma
Intrahepatic long‐term persistence of parvovirus B19 and its role in chronic viral hepatitis
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
Diffuse large B-cell lymphoma.
Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma.
  • S. Daum, R. Ullrich, +6 authors E. Riecken
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
...
1
2
...